Pathway for the management of acute heart failure

Critical Pathways in Cardiology

Volumn 4, Issue 1, 2005, Pages 37-42

  Herzog, Eyal ^a   Varley, Cathleen ^a   Kukin, Marrick ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Acute heart failure; Critical pathway

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; ENALAPRIL; EPLERENONE; FOSINOPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOLAZONE; METOPROLOL SUCCINATE; MILRINONE; NESIRITIDE; NORADRENALIN; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE; VALSARTAN; VASODILATOR AGENT;

ACUTE HEART FAILURE; ALGORITHM; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PATHWAY; CLINICAL PROTOCOL; DIFFERENTIAL DIAGNOSIS; DIURESIS; EMERGENCY WARD; HEART HEMODYNAMICS; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; OUTPATIENT CARE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 14844363396     PISSN: 1535282X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hpc.0000154606.55424.fc     Document Type: Article

References (19)

1. Fonarow GC, Weber JE. Rapid clinical assessment of hemodynamic profiles and targeted treatment of patients with acutely decompensated heart failure. Clin Cardiol. 2004;27(suppl V):V-1-V-9.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: a report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001. American College of Cardiology web site. Available at: http://www.acc. org/clinical/guidelines/failure/hf_index.htm. J Am Coll Cardiol. 2001;38:2101-2113.
3. Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail. 2002;4:11-22.
4. Mary FH, Richard OC, John MF. AHA 2000 Handbook of Emergency Cardiovascular Care for Healthcare Providers. American Heart Association; 2000.
5. Shah MR, Stevenson LW. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE). American Heart Association Scientific Sessions; New Orleans, LA; November 9, 2004.
6. Herzog E, Saint-Jacques H, Rozanski A. The PAIN pathway as a tool to bridge the gap between evidence and management of acute coronary syndrome. Critical Pathways in Cardiology. 2004;3:20-24.
7. Maisel SA, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
8. Stevenson LW. Tailored therapy of hemodynamic goals for advanced heart failure. Eur J Heart Fail. 1999;1:252-257.
9. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-1804.
10. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infraction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
11. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
12. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advance chronic heart failure. N Engl J Med. 2004;350:2140-2150.
13. Bukharovich IF, Kukin ML. Optimal medical therapy for heart failure. Prog Cardiovasc Dis. 2005. In press.
14. Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensation heart failure. J Am Coll Cardiol. 2004;43:1534-1541.
15. McMurray JJV, Östergren J, Sweedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors; the CHARM-Added trial. Lancet. 2003;362:767-771.
16. Pitt B, Zannad F, Renne WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
17. Pitt B, Willem R, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with ventricular dysfunction after myocardial infraction. N Engl J Med. 2003;348:1309-1321.
18. Juurklink D, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
19. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.